,16,17 The phase III TOP study (NCT04695925) will compare efficacy and safety of osimertinib with osimertinib–pemetrexed–carboplatin combination in treatment-naïve patients with advanced NSCLC with concurrent EGFR and TP53 mutations. This evidence concerns the gene TP53 and non-small cell lung carcinoma.